Valuation tracker
Health and bio: private company valuations
OpenEvidence is the most valuable of 2 ranked health and bio companies, at $15B (latest priced valuation). Isomorphic Labs ($50B) has only a figure from reported talks, so it is listed after the ranking. AI drug discovery, clinical AI tools for doctors and brain-computer interfaces.
| # | Company | Valuation | Run-rate revenue | Multiple | IPO status | Valuation date |
|---|---|---|---|---|---|---|
| 1 | OpenEvidence | $15BSource tier: Reported | Private | 21 Oct 2026 | ||
| 2 | Neuralink | $9BSource tier: Reported | Private | 2 Jun 2025 |
Not ranked: valuations from reported talks
| Company | Valuation | Run-rate revenue | Multiple | IPO status | Valuation date |
|---|---|---|---|---|---|
| Isomorphic Labs | $50BSource tier: Reported | Private | 17 Nov 2026 |
Information only, not investment advice. Figures are from public sources; tiers show how solid each one is.
Sources
- The Next Web (citing Bloomberg). thenextweb.com, Source tier: Reported
- Ars Technica. arstechnica.com, Source tier: Reported
- Reuters. reuters.com, Source tier: Reported